Panbela Therapeutics logo
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Our Science
    • Overview of Assets
    • Science
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Newsroom
    • Press Releases
    • Events & Presentations
  • Investor Relations
    • Corporate Governance
    • Financial Information
    • Annual Reports & Proxy Statements
    • Investor Contact Info
  • Contact

Annual Reports & Proxy Statements

  • Overview
  • Corporate Governance
  • Financial Information
  • Annual Reports & Proxy Statements
  • Investor Contact Information

Panbela 2021 Annual Report including 2022 Proxy Statement »
Sun BioPharma 2020 Annual Report including 2021 Proxy Statement »
Sun BioPharma 2019 Annual Report including 2020 Proxy Statement »
Sun BioPharma 2018 Annual Report including 2019 Proxy Statement »
Sun BioPharma 2017 Annual Report including 2018 Proxy Statement »
Sun BioPharma Notice of Consent Solicitation »
Sun BioPharma 2016 Annual Report including 2017 Proxy Statement »
Sun BioPharma 2015 Annual Report including 2016 Proxy Statement »

Quick Links

  • Home
  • About Us
  • Our Science
  • Newsroom
  • Investor Relations
  • Contact

Contact

ir@panbela.com
 
Sign up to receive press releases via email:

News & Events

Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Provides Business Update and Reports Q3 2022 Financial Results

Panbela Schedules Conference Call on Nov 10, 2022 to Report 2022 Third Quarter Financial Results

Copyright ©2022 Panbela Therapeutics, Inc. All Rights Reserved.